MGRX stock

Mangoceuticals, Inc. Common Stock (MGRX) financials · rev $456.0K

Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT

Mangoceuticals, Inc. Common Stock (MGRX) rev $456.0K.

Cached annual income statement
LineFY2025FY2024
Revenue$456.0K$615.9K
Cost of RevenueN/AN/A
Gross Profit$250.4K$380.0K
Operating Income-$18.0M-$7.97M
Net Income-$20.6M-$8.71M

Cost of Revenue N/A — Withheld: stored cost of revenue does not reconcile with revenue and gross profit for this period.

Cached annual balance sheet
LineFY2025FY2024
Total Assets$16.1M$15.4M
Current Assets$1.55M$75.6K
Cash & Equivalents$1.49M$58.7K
PP&E$1.79K$2.81K
Total Liabilities$890.6K$1.43M
Current Liabilities$890.6K$1.43M
Shareholders' Equity$15.2M$13.9M
Retained Earnings-$40.6M-$20.8M
Cached annual cash flow
LineFY2025FY2024
Operating Cash Flow-$5.85M-$4.86M
Investing Cash FlowN/A$65.0K
Financing Cash Flow$7.27M$4.13M
These statements as JSON? API free 100/day

FAQ

What is MGRX P/E and revenue?

Mangoceuticals, Inc. Common Stock (MGRX) rev $456.0K.

What is MGRX revenue?

Mangoceuticals, Inc. Common Stock last cached revenue is $456.0K (FY2025).

Is MGRX profitable?

Mangoceuticals, Inc. Common Stock last cached net income is -$20.6M (FY2025).

What are MGRX total assets?

Mangoceuticals, Inc. Common Stock last cached total assets are $16.1M (FY2025).

What is MGRX free cash flow?

No cached cash-flow row for MGRX yet.

Not investment advice. Cached statements, not a live tape.